Skip to main content


This clinical trial will investigate if home High-Flow Therapy (HFT) improves 12-month admission-free survival (time to readmission or death) following a severe exacerbation of COPD requiring hospitalisation. This is an area of unmet need, given the demonstrable limitations to current interventions which are costly, have extensive side-effects, limited availability and variable efficacy. If this this clinical trial demonstrates clinical and cost effectiveness of HFT, this technology could be rapidly incorporated into routine NHS clinical practice.

Open sites: 

  • GSTT
  • Leeds
  • Hywel Dda
  • Liverpool
  • Royal Free

Recruitment to 31/01/2024: 30/502


To identify whether home HFT in addition to usual medical care improves 12-month admission-free survival following hospitalisation with a non-hypercapnic exacerbation of COPD.

Trials Design

This is a multi-centre randomised controlled trial in which patients hospitalised with COPD exacerbation are randomised to receive home HFT and usual care or usual care alone with a 12-month follow-up period.

Project status: Ongoing



Funding Body: ResMed

Amount: £1,129,968

Period: March 2023 - February 2027

Contact us

Gill Arbane